Enzalutamide and analytical interferences in digoxin assays

References

• Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787–790.
   PubMed Web of Science ®Google Scholar
• Weiss J, Kocher J, Mueller C, et al. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharm Drug Dispos. 2017;38:517–525.
   PubMed Web of Science ®Google Scholar
• IMS Health. National Prescription Audit Plus (NPA). Plymouth Meeting; Pennsylvania (PA): IMS Health; 2012c. p. 2008–12.
   Google Scholar
• Mowry JB, Spyker DA, Cantilena LR, et al. 2013. Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 2014;52:1032–1283.
   PubMed Web of Science ®Google Scholar
• Hack JB, Cardioactive steroids. In: Goldfrank’s Toxicologic Emergencies. 9th Ed. New York (NY): McGraw Hill; 2011. p. 936–945.
   Google Scholar
• Dasgupta A. Therapeutic Drug Monitoring of digoxin: impact of endogenous and exogenous digoxin-like immunoreactive substances. Toxicol Rev. 2006;25:273–281.
   PubMedGoogle Scholar
• Adams KF, Butler J, Patterson JH, et al. Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. Eur J Heart Fail. 2016;18:1072–1081.
   PubMed Web of Science ®Google Scholar
• Fink SL, Robey TE, Tarabar AF, et al. Rapid detection of convallatoxin using five digoxin immunoassays. Clin Toxicol (Phila). 2014;52:659–663.
   PubMed Web of Science ®Google Scholar
• Mowry JB, Burdmann EA, Anseeuw K, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol (Phila). 2016;54:103–114.
   PubMed Web of Science ®Google Scholar
• Steimer W, Müller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem 2002;48:507–516.
   PubMed Web of Science ®Google Scholar
• Turcant A, Premel-Cabic A, Cailleux A, et al. Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. Clin Chem. 1991;37:1210–1215.
   PubMed Web of Science ®Google Scholar
• Jones TE, Morris RG. Discordant Results from “real-world” patient samples assayed for digoxin”. Ann Pharmacother. 2008;42:1797–1803.
   PubMed Web of Science ®Google Scholar
• Rogers NM, Jones TE, Morris RG. Frequently discordant results from therapeutic drug monitoring for digoxin: clinical confusion for the prescriber: Discordant digoxin results. Intern Med J. 2010;40:52–56.
   PubMed Web of Science ®Google Scholar
• Yamada T, Suzuki K, Iguchi K, et al. Interference between eplerenone and digoxin in fluorescence polarization immunoassay, microparticle enzyme immunoassay, and affinity column-mediated immunoassay. Ther Drug Monit. 2010;32:774–777.
   PubMed Web of Science ®Google Scholar
• Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol. 2002;118:132–140.
   PubMed Web of Science ®Google Scholar
• Rainey P. Digibind and free digoxin. Clin Chem. 1999;45:719–721.
   PubMed Web of Science ®Google Scholar
• McMillin GA, Owen WE, Lambert TL, et al. Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays. Clin Chem. 2002;48:1580–1584.
   PubMed Web of Science ®Google Scholar
• Morris RG, Frewin DB, Taylor WB, et al. The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassays. Eur J Clin Pharmacol. 1988;34:233–239.
   PubMed Web of Science ®Google Scholar
• Steimer W. “Lack of clinically significant interference by spironolactone with the Axsym Digoxin II assay” only applies to low-dose therapy with spironolactone”. Ther Drug Monit. 2003;25:484–485.
   PubMed Web of Science ®Google Scholar
• Okazaki M, Tanigawara Y, Kita T, et al. Cross-reactivity of TDX and OPUS immunoassay systems for serum digoxin determination. Ther Drug Monit. 1997;19:657–662.
   PubMed Web of Science ®Google Scholar
• Ko RJ, Greenwald MS, Loscutoff SM, et al. Lethal ingestion of Chinese herbal tea containing ch'an su. West J Med. 1996;164:71–75.
   PubMedGoogle Scholar
• Panesar NS. Bufalin and unidentified substance(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem 1992;38:2155–2156.
   PubMed Web of Science ®Google Scholar
• Fushimi R, Amino N. [Digoxin concentration in blood]. Rinsho Byori. 1995;43:34–40.
   PubMedGoogle Scholar
• Reyes MA, Actor JK, Risin SA, et al. Effect of Chinese medicines Chan Su and Lu-Shen-Wan on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. Ther Drug Monit. 2008;30:95–99.
   PubMed Web of Science ®Google Scholar
• Chow L, Johnson M, Wells A, et al. Effect of the traditional Chinese medicines Chan Su, Lu-Shen-Wan, Dan Shen, and Asian ginseng on serum digoxin measurement by Tina-quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal. 2003;17:22–27.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Actor JK, Olsen M, et al. In vivo digoxin-like immunoreactivity in mice and interference of Chinese medicine Danshen in serum digoxin measurement: elimination of interference by using a chemiluminescent assay. Clin Chim Acta Int J Clin Chem. 2002;317:231–234.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Welsh KJ, Hwang S-A, et al. Bidirectional (negative/positive) interference of oleandrin and oleander extract on a relatively new Loci digoxin assay using Vista 1500 analyzer. J Clin Lab Anal. 2014;28:16–20.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Klein K, Risin SA, et al. Rapid detection of oleander poisoning by Dimension Vista digoxin assay (Flex Reagent Cartridge). J Clin Lab Anal. 2011;25:105–109.
   PubMed Web of Science ®Google Scholar
• McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ Can Med Assoc J J Assoc Medicale Can 1996;155:293–295.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Tso G, Wells A. Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. J Clin Lab Anal. 2008;22:295–301.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Reyes MA. Effect of Brazilian, Indian, Siberian, Asian, and North American Ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol. 2005;124:229–236.
   PubMed Web of Science ®Google Scholar
• Bechtel LK, Lawrence DT, Haverstick D, et al. Ingestion of false hellebore plants can cross-react with a digoxin clinical chemistry assay. Clin Toxicol. 2010;48:435–442.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Kidd L, Poindexter BJ, et al. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. Arch Pathol Lab Med. 2010;134:1188–1192.
   PubMed Web of Science ®Google Scholar
• Ingels M, Rangan C, Morfin J-P, et al. Falsely elevated digoxin level of 45.9 ng/mL due to interference from human antimouse antibody. J Toxicol Clin Toxicol. 2000;38:343–345.
   PubMed Web of Science ®Google Scholar
• Krykbaev RA, Tsantili P, Jeffrey PD, et al. Modifying specificity of antidigoxin antibodies using insertional mutagenesis. Protein Sci. 2009;11:2899–2908.
   Web of Science ®Google Scholar
• Dasgupta A. Impact of interferences including metabolite crossreactivity on therapeutic drug monitoring results. Ther Drug Monit. 2012;34:496–506.
   PubMed Web of Science ®Google Scholar
• DeFrance A, Armbruster D, Petty D, et al. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone. Ther Drug Monit. 2011;33:128–131.
   PubMed Web of Science ®Google Scholar
• Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic Drug Interaction Studies with Enzalutamide. Clin Pharmacokinet. 2015;54:1057–1069.
   PubMed Web of Science ®Google Scholar